Free Trial
NASDAQ:ORMP

Oramed Pharmaceuticals 8/13/2025 Earnings Report

Oramed Pharmaceuticals logo
$2.12 0.00 (0.00%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.12 +0.00 (+0.24%)
As of 07/18/2025 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oramed Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

Oramed Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oramed Pharmaceuticals Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oramed Pharmaceuticals Earnings Headlines

Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Oramed Pharm Extends Stock Buyback Program
See More Oramed Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oramed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oramed Pharmaceuticals and other key companies, straight to your email.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (NASDAQ:ORMP) is a clinical-stage biopharmaceutical company specializing in the development of proprietary oral drug delivery systems. Founded in 2006 and headquartered in Jerusalem with U.S. offices in New York, Oramed’s core focus is on transforming injectable therapies into orally administered formulations. The company was established by Dr. Nadav Kidron, who remains at the helm as Chief Executive Officer, guiding Oramed’s strategy to address chronic diseases through patient-friendly oral alternatives.

Oramed’s lead candidate, ORMD-0801, is an oral insulin capsule designed to improve glycemic control in patients with type 2 diabetes. This product has advanced through multiple Phase II clinical trials, demonstrating the potential to reduce postprandial glucose excursions and lower HbA1c levels. In addition to insulin, Oramed is advancing ORMD-0901, an oral formulation of exenatide, and a proprietary oral GLP-1 analog program aimed at obesity and metabolic syndrome, highlighting the company’s commitment to innovation in metabolic disease management.

The company operates globally, conducting clinical trials and forging strategic partnerships across North America, Europe, India and Asia. In 2021, Oramed launched Oravax Medical, a subsidiary focused on developing an oral COVID-19 vaccine; it has since expanded its pipeline to include oral vaccine candidates for influenza and other respiratory pathogens. Oramed’s collaborations with academic institutions and contract manufacturers in India and China further underscore its strategy to accelerate development and broaden market access.

Under the leadership of CEO Nadav Kidron and a management team with extensive experience in pharmaceutical R&D, regulatory affairs and commercialization, Oramed is positioned to address significant unmet needs in diabetes care and beyond. The company continues to leverage its proprietary Capsule Technology Platform to advance multiple oral therapeutic candidates, aiming to improve patient adherence and outcomes in chronic disease treatment.

View Oramed Pharmaceuticals Profile

More Earnings Resources from MarketBeat